arrow
B

Bhausaheb Bagal

tata memorial centre (tmc)
H指数:17
被引数:1,167

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety

为复发/难治性B细胞恶性疾病启用talicabtagene autoleucel的获取途径;关于其配送、有效性和安全性的多中心真实世界证据

2026-07-160
OA
Defining alteration in bone marrow mesenchymal stem cells (MSC) from acute myeloid leukemia and exploring cultured MSC-conditioned media as a novel anti-leukemia therapy agent

定义急性髓系白血病中骨髓间充质干细胞(MSC)的异常改变,并探讨培养的MSC条件培养基作为新型抗白血病治疗剂的应用。

2026-02-230
OAAI
Is looking at the tip of the iceberg sinking our ship? A longitudinal cohort study on the patterns of evolution on treatment of non-enhancing FLAIR lesions in primary CNS lymphoma

关注非增强FLAIR病灶的治疗演变模式是否只是冰山一角?一项关于原发性CNS淋巴瘤非增强FLAIR病灶治疗演变模式的纵向队列研究

2026-02-190
PRE
TGFβ-Mediated Overexpression of Podoplanin Serves as a Potential Diagnostic Biomarker in Acute Promyelocytic Leukemia

TGFβ介导的Podoplanin过表达可作为急性早幼粒细胞白血病的潜在诊断生物标志物

2026-02-010
OAAI
Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia

Venetoclax通过诱导线粒体凋亡和自噬来克服急性早幼粒细胞白血病中的三氧化二砷耐药性。

2026-01-120
OAAI
Is Less “Sufficient” and “Safe” in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma

在微小残留病时代,更少的剂量是否“足够”且“安全”?——根据美法仑剂量评估多发性骨髓瘤患者自体干细胞移植的结局

2026-01-080
OAAI
Real World Data on Demographics, Management and Outcome of Ultra High-Risk Myeloma - Experience from a Tertiary Care Centre

超高危骨髓瘤的人口统计学、治疗和结局的真实世界数据——来自一家三级护理中心的经验

2026-01-010
PRE
Addressing unmet needs in chronic myeloid leukemia in chronic phase treated with two or more tyrosine kinase inhibitors: insights from literature and Indian clinical practice

针对接受两种或多种酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病未满足需求的探讨:文献与印度临床实践的启示

2026-01-010
PRE
Multiple Myeloma in Young Adults-Insights From a Tertiary Care Cancer Centre in India

青年多发性骨髓瘤——来自印度一家三级护理癌症中心的研究见解

2025-12-010
OAAI
Attrition Rates in Multiple Myeloma - A Report from indian Patients at A Tertiary Cancer Center

多发性骨髓瘤患者的流失率——来自印度某三级癌症中心的患者报告

2025-12-010
OAAI
Clinical characteristics, treatment pathway and resource utilisation for patients with chronic lymphocytic leukaemia: A multicentre retrospective study

慢性淋巴细胞白血病患者临床特征、治疗路径及资源利用:一项多中心回顾性研究

2025-12-011
PRE
Treatment free remission (TFR) in chronic myeloid leukemia—results, compliance and patterns of failure from a tertiary care cancer centre in India

慢性髓性白血病中的无治疗缓解(TFR)——来自印度一家三级护理癌症中心的结果、依从性及失败模式

2025-10-310
OA
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India

关于多发性骨髓瘤可测量残留病灶的德尔菲调查:印度的现行实践及未来方向

2025-05-210
PRE
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study (vol 15, 75, 2025)

新型人源化CD19-CAR-T(现名为talicabtagene autoleucel,Tali-cel™)细胞在复发/难治性儿童B急性淋巴细胞白血病中的应用——一项开放标签单臂I/Ib期研究(卷15,第75期,2025年)

2025-05-200
OA